methyl-(1-methyl-2-phenyl-propyl)-amine | 64969-62-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl-(1-methyl-2-phenyl-propyl)-amine
• 英文别名: Methyl-(1-methyl-2-phenyl-propyl)-amin；N-methyl-3-phenylbutan-2-amine
• CAS: 64969-62-6
• 化学式: C₁₁H₁₇N
• 分子量: 163.263
• InChiKey: VLCNEVLBEFFUMR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  3-羟基-3-苯基丁烷-2-酮 、 甲胺 在 甲醇 、 水 、 氢化铝 作用下， 生成 methyl-(1-methyl-2-phenyl-propyl)-amine
  参考文献：
  名称：

  DE833042

  摘要：

  公开号：

文献信息

• NEMATICIDAL N-(PHENYLCYCLOALKYL)CARBOXAMIDES AND N-(PHENYLCYCLOALKYL)THIOCARBOXAMIDES
  申请人：BAYER CROPSCIENCE AKTIENGESELLSCHAFT

  公开号：US20160075653A1

  公开（公告）日：2016-03-17

  The present invention relates to the use of N-(Phenylcycloalkyl)carboxamides and N-(Phenylcycloalkyl)thiocarboxamides for the control of nematodes in agriculture and as anthelmintic agents against endoparasites in animals and humans, compositions containing such compounds and methods for the control of nematodes and helminths and furthermore to novel N-(Phenylcycloalkyl)carboxamides and N-(Phenylcycloalkyl)thiocarboxamides, processes and intermediate compounds for their preparation, their use as nematicides, compositions containing such compounds and methods for the control of nematodes.

  本发明涉及使用N-(苯基环烷基)羧酰胺和N-(苯基环烷基)硫代羧酰胺来控制农业中的线虫，以及作为动物和人类内寄生虫的驱虫剂，包含这些化合物的组合物和控制线虫和蠕虫的方法，此外还涉及新的N-(苯基环烷基)羧酰胺和N-(苯基环烷基)硫代羧酰胺、制备它们的过程和中间化合物，它们的用途作为线虫杀剂，包含这些化合物的组合物以及控制线虫的方法。
• 5-HT2C Receptor Agonists as Anorectic Agents
  申请人：Kozikowski Alan

  公开号：US20090203750A1

  公开（公告）日：2009-08-13

  This invention relates to compounds which modulate receptors of the 5-HT2 family of receptors, and particularly to compounds which modulate 5-HT2C receptors. Compounds of the invention include agonists and selective agonists for the 5-HT2C receptor Compounds of the invention include selective agonists for the 5-HT2C receptor which exhibit significantly less or no agonist activity on the 5-HT2A receptor and/or the 5-HT2B receptor. Compounds of this invention are those of Formula I and pharmaceutically acceptable salts, esters and solvates (including hydrates) wherein variables are defined in the specification hereof.

  本发明涉及调节5-HT2家族受体的化合物，特别是调节5-HT2C受体的化合物。本发明的化合物包括5-HT2C受体的激动剂和选择性激动剂。本发明的化合物包括5-HT2C受体的选择性激动剂，其在5-HT2A受体和/或5-HT2B受体上表现出显著较少或无激动剂活性。本发明的化合物包括式I和药学上可接受的盐、酯和溶剂（包括水合物），其中变量在本规范中定义。
• NODULISPORIC ACID DERIVATIVES
  申请人：Merck & Co., Inc.

  公开号：EP0819000B1

  公开（公告）日：2009-07-08
• COMBINATION THERAPY FOR EFFECTING WEIGHT LOSS AND TREATING OBESITY
  申请人：VIVUS, INC.

  公开号：US20140308346A1

  公开（公告）日：2014-10-16

  The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss. The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.
• Compositions and Methods for the Treatment of Sleep Apnea
  申请人：VIVUS, INC.

  公开号：US20150025134A1

  公开（公告）日：2015-01-22

  The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss. The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.